EULAR Study Group on Microcirculation in Rheumatic Diseases (SG MC/RD)

Slides:

Advertisements

Similar presentations

Diabetes and the Health Innovation Network Charles Gostling 19 September, 2013.

Advertisements

Renee Otter WP5 leader. Health Strategies in Europe. Lisbon, July Coleman M.

VU University Medical Center Amsterdam The Netherlands 3 rd International ELN Workshop: Standardization of Flow Cytometry in MDS London, Greenwich 4-6.

Criteria for Centres of Expertise for Rare Diseases in the EU following EUCERD Recommendations RARECARENet Project: Consensus meeting on.

COI Network III Training, Master Class, Good Practice The COI Network III Training, Master Class, Good Practice 1st Oct 2006 – 30 Nov 2007 COI related.

1 Progress report: DISCONTOOLS Project Morgane Delavergne DISCONTOOLS Project Manager, September 22nd, 2009 Mirror Group Meeting Châtelain Hotel, Brussels.

Operational Research in the 21 st Century. International Union Against Tuberculosis and Lung Disease (The Union) World’s oldest humanitarian organization.

March 2015 Inter-American Network for the Prevention of Violence and Crime.

Author: Cumurciuc Mihai Co-author:Silvia Ioana Morar Coordinator: Dr. Parvu Mirela.

Yasser El-Wazir, MBBCh, PhD Director of quality Center, SCU Professor of Physiology Faculty of Medicine, Suez Canal University.

Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.

NASCE: Programme requirements Paul Ridgway. Need for NASCE? Cost of Skills training Pressures for training outside service hours Pressures for training.

Monitoring, reporting and evaluating climate change adaptation policies at national level in Europe - An overview of where we stand Stéphane Isoard, EEA.

Second European Eye Epidemiology Workshop Bordeaux June 28-29, 2012.

2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative An.

Sjogren’s syndrome Study Group EULAR Sjogren’s Syndrome Experimental and Translational investigative Alliance Francesca Barone, Tim Radstake, Fai Ng on.

Horizon 2020 – R&D Opportunities

Mobility of Italian citizens in EU and Efta countries

Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) Progress Reports June 2005 Presented CIFASD Steering Committee Meeting Santa Barbara,

EULAR Foot & Ankle Study Group

Director of Policy Analysis and Research

Experiences of the Association of European Election Officials as ACE Regional Centre Overview First part of 2009 Stockholm, Sweden, June 2009.

Musculoskeletal Health in Europe

WP 4 – EPIDEMIOLOGY GEMMA Gatta

Yulia Mikhaylova Chair Expert Group on Primary Healthcare

Daniela B. Friedman, University of South Carolina

EULAR Study Group on Microcirculation in Rheumatic Diseases (SG MC/RD) V. Smith*1, A. Herrick2, A. Sulli3 and M. Cutolo3 1Ghent University Hospital, University.

Francesca Barone on behalf of Essential study group.

Preventing VTE in hospitalised patients

EULAR Study Group for Collaborative Research

Grampian COPD MCN Delivering Spirometry in a Community Pharmacy setting, a rural solution? Small I (1,2), Clelland J (1,2), Robertson W (1), Freeman D.

Project Name: Country:

Diffuse Idiopathic Skeletal Hyperostosis (DISH) Study Group

Content: EuReCa TWO About the study Timeline Contacts I. Structure

EULAR Study Group on patient education

EULAR Study Group on Osteoarthritis

ERN skin Coordinator: Prof. Christine Bodemer

AESS Short Course Joe Fabrizio September 28-29, 2018

EULAR Study Group on Registers and Observational Drug Studies (RODS)

The EMPIR NeuroMET project

The International Consortium for Personalised Medicine

The 2010 World Population and Housing Census Programme

EULAR Psychology Study Group

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Network of Methodologists

COST and COST Actions Participation of Georgian researchers

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR50, (B) CDAI LDA and (C) HAQ-DI

Disease activities evaluated as a comparison between abatacept plus MTX and placebo plus MTX groups. Disease activities evaluated as a comparison between.

Efficacy outcomes in patients aged ≥65 years versus younger patients: ACR outcomes at (A) week 12 and (B) week 24. Efficacy outcomes in patients aged ≥65.

The New Biogeographic Process General info – December 2011

Clinical response in patients with early and established RA at month 24. *p

Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.

Improvement in PROs, TJC, SJC and PGA at month 6 in patients achieving (A) ACR70, (B) CDAI REM and (C) SDAI REM. For tofacitinib 5 and 10 mg BID treatment.

Improvement in FACIT-F fatigue score according to ACR20 response status (ACR, American College of Rheumatology; DMARD, disease-modifying antirheumatic.

ACR20 response rates. ACR20 response rates. ACR20 response rates based on non-responder imputation (NRI) for the 120/Q4W, 90/Q2W and placebo groups over.

Results from the second Delphi step showing the percentage of rated domains that the experts agreed on as domains for the annual systemic assessment of.

Rates of ACR50 response and prespecified MTX-related adverse events in patients in the (A) CONCERTO study over 26 weeks and (B) MUSICA study over 24 weeks. ACR50, American.

ACR20/50/70 response rates at week 24 (TP1 per-protocol set).

Synovial Biopsy in Patients with UPIA

ACR responses: (A) responses at Week 52 and Week 104

The Study Group aims to:

Percentage of responders at month 6 by (A) ACR50, SDAI/CDAI LDA, and HAQ-DI

EULAR Study group on patient education

EULAR Study Group on SLE

Projects with publication Courses, meetings and presentations in 2018

EULAR Study Group for Collaborative Research

EULAR Study Group on Osteoarthritis

Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.

Francesca Barone on behalf of Essential study group.

Increased numbers of LDGs in association with disease activity and low complement levels in patients with SLE. Numbers of LDGs were determined by flow.

Presentation transcript:

EULAR Study Group on Microcirculation in Rheumatic Diseases (SG MC/RD) V. Smith*1, A. Herrick2, A. Sulli3 and M. Cutolo3 1Ghent University Hospital, University of Ghent, Belgium, 2University of Manchester, United Kingdom, 3University of Genova, Italy Summary of last year’s activity Projects with publication (2016) SG MC/RD 1: As standardisation of techniques to evaluate the microcirculation is one of the aims of the study group, a first activity was a multicentre study to assess the reliability of simple capillaroscopic definitions to evaluate morphologies of single capillaries. This study consisted of three parts (namely evaluation of study images by experts, evaluation of study images by novices at the 6th EULAR course on capillaroscopy in Genova, September 2014 and thirdly by participants at a training course at the Ghent University, Belgium, November 2014) and resulted in a manuscript: Smith V. et al. An EULAR Study Group on reliability of simple capillaroscopic definitions to describe capillary morphology in rheumatic diseases. Rheumatology. 2016;55(5):883-890. The study group first convened at EULAR 2014 consisting of 12 founding members (Chair: Prof. V. Smith; Co-Chairs: Prof. A. Herrick, Prof. M. Cutolo, Prof. A. Sulli and other founding members: Prof. Y. Allanore, Prof. O. Distler, Prof. N. Damjanov, Prof. U. Müller-Ladner, Dr. W. Hermann, Prof. I. Murat, Dr. V. Riccieri and Prof. AE. Voskuyl) and 28 in members (from which 11 of 5 non-European countries: USA, Brasil, South Africa, Turkey and Japan). Anno 2016 the number of members has risen to 56 (out of which 17 from 8 non-European countries). Courses, meetings and presentations on behalf of the EULAR Study Group on MC RD in 2016 Annual European Congress of Rheumatology “EULAR 2016” London June 2016: Workshop on Capillaroscopy. The 7th EULAR Course on Capillaroscopy, Genoa Septembr 8-10 2016. Annual scientific meeting American College of Rheumatology “ACR Washington November 2016”. Study group on Capillaroscopy – Workshop”. EULAR London JUNE 2016: lectures: - "Differential diagnosis between primary and secondary Raynaud’s phenomenon” and “How to differentiate normal from abnormal capillaroscopic patterns: role in early diagnosis”. EULAR 2016: EULAR SG MC/RD meeting. ACR 2016: EULAR SG MC/RD meeting at ACR. ACR 2016: ACR Study Group on Capillaroscopy. SG MC/RD 2: Secondly, the evaluation of interrater reliability of microcirculatory flow evaluation (Laser Speckle Contrast Analysis) was piloted by two of the founding members and has been published: Lambrecht V. et al. Reliability of the quantitative assessment of peripheral blood perfusion by laser speckle contrast analysis in a systemic sclerosis cohort. Ann Rheum Dis. 2016;75(6):1263-1264. SG MC/RD 3: Thirdly, a cross-sectional, international SUrvey on non-iNvaSive tecHniques to assess the mIcrocirculation in patients with RayNaud’s phEnomenon (SUNSHINE survey) has been performed in between 471 eligible physicians between October and December 2015 (submitted as a manuscript) Ongoing projects SGMC/RD 4=>9 (see EULAR website) Corresponding address: vanessa.smith@ugent.be Why a Study group on Microcirculation in Rheumatic Diseases ? The EULAR Study Group on Micro-Circulation in Rheumatic Diseases (SG MC/RD) aims to build an international network of expert centres and individuals to exchange knowledge within Europe and provide a platform on which the investigators can: 1. Study (micro)vascular mechanisms involved in the progression of rheumatic musculoskeletal diseases (RMD) with (micro)vascular involvement. 2. Develop natural history investigations operating across existing cohorts of European centres interested in the cooperation and implementation of diagnostic tools on microcirculation. 3. Identify through statistical analysis (based on large samples), models based on (micro)vascular assessment tools to predict disease progression and outcome. 4. Evaluate the microvascular effects of novel target strategies within specific RMD populations Who we are? The EULAR Study Group on Microcirculation in Rheumatic Diseases was accepted by the EULAR Executive Committee in March 2014 and actually is being supervised by EULAR Committee on Investigative Rheumatology, currently chaired by Prof. X. Mariette.